Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors
AssigneeThe Regents of the University of California
InventorsJon R. Polansky, Ernest Bloom, Donald J. Fauss
Life of this patent
Estimating the term…
Abstract
Methods and compositions for preventing or treating non-inflammatory elevated intraocular pressure associated with administered or endogenous steroids including administering to a mammalian organism a composition including (a) an ophthalmologically effective amount of a non-steroidal cyclooxygenase inhibitor, and (b) a pharmaceutically acceptable carrier, to reduce or prevent an elevation of intraocular pressure and/or protein marker induction induced by chronic exposure to glucocorticoids.
Claims74
A method for preventing or treating non-inflammatory induced elevated intraocular pressure associated with administered or endogenous glucocorticoids comprising administering to a mammalian organism a composition including (a) an ophthalmologically effective amount of a non-steroidal cyclooxygenase inhibitor, and (b) a pharmaceutically acceptable carrier, to reduce or prevent an elevation of intraocular pressure induced by concurrent or previous treatment with glucocorticoids or by endogenous glucocorticoids.
A method for preventing or treating non-inflammatory induced elevated intraocular pressure associated with administered or endogenous glucocorticoids comprising administering to a mammalian organism a composition including (a) an opthalmically effective amount of a non-steroidal anti-inflammatory agent, and (b) a pharmaceutically acceptable carrier to arrest processes damaging to the eye resulting from chronic exposure of the eye to glucocorticoids.
A method for preventing damage to or treating damage to human trabecular meshwork cells associated with treatment of the eye with glucocorticoids comprising administering a composition to a mammalian organism having been treated or being treated with glucocorticoids, said composition including an opthalmically effective amount of a non-steroidal anti-inflammatory agent and an inert carrier.
A composition adapted for preventing or treating non-inflammatory induced elevated intraocular pressure associated with administered or endogenous steroids comprising (a) an ophthalmically effective amount of between 0.001 and about 0.009% by weight of a non-steroidal cyclooxygenase inhibitor of a type to reduce or prevent an elevation of intraocular pressure induced by concurrent or previous treatment with glucocorticoids, and (b) a pharmaceutically acceptable carrier therefor.
Dependencies are inferred from the claim text.